Bydureon
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
La prevalence du diabete de type II est aujourd'hui en constante augmentation. Cette derniere est profondement liee aux…
Type 2 diabetes is still rapidly on the rise today, affecting 10.5% of individuals in the United States between the ages 45 to 64…
: Bydureon is a new galenic formulation (long-acting release) of exenatide, the first agonist of Glucagon-Like Peptide-1 (GLP-1…
®est une nouvelle forme galenique, a liberation prolongee, de l’exenatide, premier agoniste des recepteurs du Glucagon-Like…
Bristol-Myers Squibb och AstraZeneca tar over rattigheterna for Byetta och Bydureon (exenatide) fran Eli Lilly
Bydureon is a long‐acting formulation of exenatide administered as a once‐weekly injection. The authors present the clinical data…
Mechanism of Action: 1,2,3,4, : Incretins, such as glucagon-like peptide-1 (GLP-1), enhance glucose-dependent insulin secretion…
FDA has approved exenatide extended-release for injectable suspension (Bydureon, Amylin and Alkermes) ? the first once-weekly…